(IN BRIEF) AstraZeneca announced positive interim Phase III VOLGA trial results showing that perioperative Imfinzi combined with neoadjuvant enfortumab vedotin significantly improved event-free survival and overall survival in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, AstraZeneca Expands Immunotherapy Momentum in Bladder Cancer with Positive Phase III VOLGA Trial Readout, AstraZeneca oncology, bladder cancer, Cancer Immunotherapy, cancer recurrence, cancer treatment, cisplatin-ineligible patients, clinical trial results, CTLA-4, durvalumab, enfortumab vedotin, EV, event-free survival, Imfinzi, Imjudo, immunotherapy, MIBC, muscle-invasive bladder cancer, NIAGARA trial, NILE trial, oncology, oncology research, overall survival, PD-L1 inhibitor, Phase III Trial, POTOMAC trial, radical cystectomy, survival outcomes, Susan Galbraith, Thomas Powles, tremelimumab, urothelial carcinoma, VOLGA Phase III Results Position AstraZeneca’s Imfinzi Regimen as Promising New Option for Cisplatin-Ineligible Bladder Cancer Patients, VOLGA trial
(IN BRIEF) The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) combined with gemcitabine and cisplatin as neoadjuvant therapy, followed by Imfinzi adjuvant monotherapy, for adults with resectable muscle-invasive bladder cancer. This approval is anchored in NIAGARA Phase III trial data … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged adjuvant monotherapy, AstraZeneca, cisplatin, curative intent, Dave Fredrickson, durvalumab, ESMO, European Commission, event-free survival, gemcitabine, Imfinzi, immunotherapy, MIBC, Michiel Van der Heijden, muscle-invasive bladder cancer, neoadjuvant chemotherapy, New England Journal of Medicine, NIAGARA Phase III, NMIBC, overall survival, radical cystectomy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?